Past Events

Christopher Buckley

"A therapeutic cell atlas to study Immune-Mediated Inflammatory Diseases”

Lecture

Unlike haematological diseases where the gene (haemoglobin), cell (red blood cell) and clinical features (anaemia) map well onto each other, the cellular basis for most inflammatory diseases remains enigmatic. The Human Cell Atlas (HCA) [1] was established to construct a map of the different cell types involved in forming human organs using single cell analysis with spatial analysis to locate their position in tissue. Using the principles of the HCA in an Arthritis Therapy Acceleration Programme (A-TAP) we have assessed how the cellular composition of tissue is affected following treatment with biologics such as anti TNF across a range of IMIDs including RA and IBD [2]. This therapeutic cell atlas can be used to instruct and power experimental medicine studies where a common cell-based marker [3] is used in Bayesian driven basket trials as a common outcome measure in the study [4].

References

  1. https://www.humancellatlas.org/
  2. Immune-mediated inflammation across disease boundaries: breaking down research silos. Buckley CD, Chernajovsky L, Chernajovsky Y, Modis LK, O'Neill LA, Brown D, Connor R, Coutts D, Waterman EA, Tak PP. Nat Immunol. 2021 Nov;22(11):1344-1348. doi: 10.1038/s41590-021-01044-7. PMID: 34675389
  3. Cross-tissue, single-cell stromal atlas identifies shared pathological fibroblast phenotypes in four chronic inflammatory diseases. Korsunsky I, Wei K, Pohin M, Kim EY, Barone F, Major T, Taylor E, Ravindran R, Kemble S, Watts GFM, Jonsson AH, Jeong Y, Athar H, Windell D, Kang JB, Friedrich M, Turner J, Nayar S, Fisher BA, Raza K, Marshall JL, Croft AP, Tamura T, Sholl LM, Vivero M, Rosas IO, Bowman SJ, Coles M, Frei AP, Lassen K, Filer A, Powrie F, Buckley CD, Brenner MB, Raychaudhuri S. Med . 2022 May 26:S2666-6340(22)00184-2 oi: 10.1016/j.medj.2022.05.002.  PMID: 35649411
  4. https://www.kennedy.ox.ac.uk/about/translational-research/ata

Biography

Christopher Buckley obtained a degree in Biochemistry from the University of Oxford (1985) with subsequent undergraduate training in Medicine (MBBS) at the Royal Free Hospital, London (1990). His postgraduate medical training was in General Medicine and Rheumatology at the Hammersmith Hospital, London (Mark Walport, Dorian Haskard), and John Radcliffe Hospital, Oxford. He obtained a DPhil arising from a Wellcome Trust Clinical Training Fellowship with John Bell and David Simmons at the Institute Molecular Medicine, Oxford in 1996.

Funded by a Wellcome Trust Clinician Scientist Fellowship, he joined the Department of Rheumatology in Birmingham later that year. In 2001 he was awarded an MRC Senior Clinical Fellowship and in 2002 became Arthritis Research UK Professor of Rheumatology. In 2012 he was appointed Director of the Birmingham NIHR Clinical Research Facility.

In May 2017 he took up a new joint academic post between the Universities of Birmingham and Oxford at the Kennedy Institute of Rheumatology Oxford and Director of NIHR Infrastructure in Birmingham for Birmingham Health Partners to Direct the Arthritis Therapy Acceleration Programme(A-TAP). In September 2021 he moved to the Kennedy Institute of Rheumatology Oxford as Director of Clinical Research

https://www.kennedy.ox.ac.uk/team/christopher-buckley

15 Aug 2023

GCIR 2023 Symposium Speakers